학술논문
Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohnʼs Disease: Results From the CHARM Trial
Document Type
Academic Journal
Author
Source
American Journal of Gastroenterology. May 01, 2009 104(5):1170-1179
Subject
Language
English
ISSN
0002-9270
Abstract
OBJECTIVES:: METHODS:: RESULTS:: Results for all outcome measures were superior for both continuous groups compared with the induction only/reinitiation group. On the basis of median CDAI and IBDQ results, patients in both continuous treatment groups achieved statistically significantly greater improvements vs. the induction only/reinitiation group (P<0.05). At week 56, a significantly greater percentage of patients who had received continuous adalimumab (51% for e.o.w. and 49% for weekly) were in clinical remission vs. the induction only/reinitiation group (38%, P < 0.05). Continuous adalimumab therapy was also associated with fewer flares and fewer CD-related surgeries (P<0.05). Patients in both continuous adalimumab groups had significantly lower risks of CD-related and all-cause hospitalizations than did patients in the induction only/reinitiation group (P<0.05). CONCLUSIONS